Efficacy and safety of paliperidone extended-release tablets in the treatment of schizophrenia
10.3760/cma.j.issn.1008-6706.2018.05.006
- VernacularTitle:帕利哌酮缓释片治疗精神分裂症的临床效果及安全性
- Author:
Qunfen WANG
1
Author Information
1. 慈溪市第七人民医院精神科
- Keywords:
Schizophrenia;
Paliperidone extended-release tablets;
Risperidone;
Safety
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(5):566-569
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical effect and safety of paliperidone extended-release tablets in the treatment of schizophrenia.Methods 80 patients with schizophrenia were selected as the research subjects .Accord-ing to randomized single blind,the patients were divided into two groups ,40 cases in each group.The control group was given risperidone treatment,the observation group used paliperidone extended-release tablets treatment.The total effective rate,positive and negative symptoms score (PANSS score),mental disability score (WHO-DAS score II) and the incidence of adverse reactions were compared between the two groups .Results The clinical total effective rate (95.00%) in the observation group was significantly higher than the control group (80.00%,χ2 =4.114,P <0.05).After treatment, the PANSS score and WHO-DAS II score in the observation group were significantly decreased compared with before treatment (t =8.002,7.761,all P <0.05),which were lower than those in the control group after treatment (t =4.114,3.702,all P <0.05).The incidence rate of adverse reaction between the two groups had no statistically significant difference (7.50% vs.10.00%,χ2 =0.157,P >0.05).Conclusion The clinical efficacy of paliperidone extended-release tablets in the treatment of schizophrenia is significant ,which can effectively relieve patients with mental disorders ,and it is safe and reliable.
